A Phase 2 interventional study of MenABCWY vaccine and rMenB+OMV NZ (Bexsero) vaccine in Meningitis, Meningococcal, sponsored by GlaxoSmithKline. Completed at 1 site in Czechia. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-12.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the current study is to evaluate whether there is immune interference when MenABCWY [consisting of MenACWY lyophilized component and rMenB+OMV NZ (Bexsero) liquid component] is administered to healthy adolescents and adults following a 2-dose vaccination schedule with MenABCWY administered 2 months apart.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
This study's enrollment of 520 is close to the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Browse Meningitis, Meningococcal studies →GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Abnormal function of the immune system resulting from:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).
Biological: MenABCWY vaccine
Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).
Biological: rMenB+OMV NZ (Bexsero) vaccine · Biological: MenACWY (Menveo) vaccine
Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).
Biological: rMenB+OMV NZ (Bexsero) vaccine · Biological: MenACWY (Menveo) vaccine
Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).
Biological: rMenB+OMV NZ (Bexsero) vaccine
Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.
Biological: MenACWY (Menveo) vaccine
Two doses administered intramuscularly in the deltoid region of the non-dominant arm.
Drug page: 4CMenB vaccineStudies of 4CMenB vaccine4CMenB vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group, rMenBOMV+ACWY_D Group and rMenBOMV Group
Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group and rMenBOMV+ACWY_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group
Human Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs) Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After Last Vaccination.
hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.
Time frame: 1 month after last vaccination i.e.: at Day 91 for all groups except for the MenACWY Group
hSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135, and Y, One Month After Last Vaccination.
hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.
Time frame: 1 month after last vaccination i.e.: at Day 91 for all groups except the MenACWY Group, and at Day 31 for the MenACWY Group.
Percentage of Subjects With hSBA Titers Greater Than or Equal to(≥) the Lower Limit of Quantitation (LLOQ) Against Each of the N. Meningitidis Serogroup B Test Strains and Serogroups A, C, W-135 and Y,One Month After Last Vaccination.
Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).
Time frame: 1 month after last vaccination i.e.: at Day 91 for all groups except the MenACWY Group, and at Day 31 for the MenACWY Group.
Percentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.
Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise was defined as: a) for individuals whose pre-vaccination titers were less than (\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).
Time frame: 1 month after last vaccination versus baseline (i.e.: at Day 91 versus Day 1 for all groups except the MenACWY Group, and at Day 31 versus Day 1 for the MenACWY Group).
hSBA Adjusted Geometric Mean Ratios (GMRs) Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.
hSBA mean ratios at 1 month after the last vaccination versus baseline were calculated in terms of GMRs i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after last vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.
Time frame: 1 month after last vaccination versus baseline (i.e.: at Day 91 versus Day 1 for all groups except the MenACWY Group, and at Day 31 versus Day 1 for the MenACWY Group).
hSBA Adjusted GMTs Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After First Vaccination
hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.
Time frame: 1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group
hSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135 and Y, One Month After First Vaccination.
hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.
Time frame: 1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group.
Percentage of Subjects With hSBA Titers Greater Than or Equal to (≥) the LLOQ Against Each of the N. Meningitidis Serogroup B Test Strains and Against Serogroups A, C, W-135, and Y, One Month After First Vaccination
Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).
Time frame: 1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group
Percentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination
Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise is defined as: a) for individuals whose pre-vaccination titers were less than (\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).
Time frame: 1 month after first vaccination versus baseline (i.e.: at Day 31 versus Day 1 for all groups except for the MenACWY Group)
hSBA Adjusted GMRs Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination
hSBA mean ratios at 1 month after the first vaccination versus baseline were calculated in terms of GMRs. i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after first vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted mean were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.
Time frame: 1 month after first vaccination versus baseline (i.e.: at Day 31 versus Day 1 for all groups except for the MenACWY Group)
Number of Subjects With Any Solicited Local Adverse Events (AEs)
Assessed local AEs were erythema, swelling, induration and pain. Any erythema, swelling and induration is defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
Time frame: During the 7 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)
Number of Subjects With Any Solicited Systemic AEs
Assessed systemic AEs were arthralgia, fatigue, nausea, headache, myalgia and fever. Any fever is defined as body temperature equal or greater than 38 degrees Celsius.
Time frame: During the 7 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)
Number of Subjects With Unsolicited AEs
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. An unsolicited AE is an AE that was not solicited using a Subject Diary and that was spontaneously communicated by a subjects/parent(s)/ Legally Acceptable Representative who has signed the informed consent or a solicited local or systemic adverse event that continues beyond the solicited period at day 7 after vaccination.
Time frame: During the 30 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)
Number of Subjects With Serious Adverse Events (SAEs), Medically Attended AEs (MAEs), AEs Leading to Withdrawal, and Adverse Events of Special Interest (AESIs)
SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Medically attended AEs are defined as symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. AESIs are predefined (serious or non-serious) adverse events of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.
Time frame: During the whole study period i.e from Day 1 to Day 91
Subjects were recruited from 1 center at Czechia.
| Milestone | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| Started | 100 | 104 | 100 | 94 | 102 |
| Completed | 100 | 104 | 100 | 94 | 102 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.
| titers | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group |
|---|---|---|---|---|
| Human Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs) Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After Last Vaccination. | 31.84 (28.18 to 35.98) | 38.48 (34.23 to 43.26) | 40.08 (35.44 to 45.33) | 42.38 (37.31 to 48.13) |
hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.
| titers | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| Meningitis B M14459 (fHbp) | 23.91 (20.52 to 27.86) | 23.34 (20.16 to 27.01) | 23.23 (19.91 to 27.10) | 22.87 (19.52 to 26.80) | 2.48 (2.13 to 2.89) |
| Meningitis B 96217(NadA) | 81.09 (69.24 to 94.97) | 102.68 (88.24 to 119.50) | 97.54 (83.18 to 114.39) | 113.54 (96.25 to 133.93) | 4.15 (3.54 to 4.86) |
| Meningitis B NZ98/254(PorA) | 12.97 (10.89 to 15.45) | 16.39 (13.86 to 19.39) | 21.12 (17.71 to 25.18) | 20.97 (17.47 to 25.16) | 2.15 (1.81 to 2.57) |
| Meningitis B M07-0241084(NHBA) | 13.08 (11.09 to 15.43) | 18.00 (15.35 to 21.11) | 22.59 (19.12 to 26.69) | 25.34 (21.30 to 30.13) | 4.08 (3.45 to 4.82) |
| Meningitis A | 104.90 (87.02 to 126.47) | 187.52 (156.94 to 224.05) | 204.01 (169.06 to 246.18) | 94.91 (78.26 to 115.12) | 52.03 (43.01 to 62.95) |
| Meningitis C | 172.99 (140.43 to 213.09) | 144.80 (118.48 to 176.97) | 145.42 (117.91 to 179.34) | 32.01 (25.75 to 39.79) | 34.66 (28.09 to 42.78) |
| Meningitis W | 260.11 (219.31 to 308.51) | 245.63 (208.40 to 289.52) | 254.20 (213.76 to 302.30) | 193.58 (161.68 to 231.76) | 80.11 (67.42 to 95.19) |
| Meningitis Y | 219.52 (173.10 to 278.39) | 186.08 (148.25 to 233.55) | 204.92 (161.40 to 260.16) | 3.66 (2.86 to 4.69) | 92.41 (72.75 to 117.37) |
Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).
| Percentage of subjects | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| Meningitis B M14459 (fHbp) | 83.5 (77.64 to 88.28) | 86.0 (80.50 to 90.35) | 88.5 (83.22 to 92.57) | 83.3 (77.18 to 88.31) | 12.4 (8.21 to 17.78) |
| Mengitis B 96217(NadA) | 96.9 (93.31 to 98.87) | 99.0 (96.17 to 99.89) | 99.0 (96.05 to 99.89) | 100.0 (97.47 to 100.00) | 33.3 (26.96 to 40.24) |
| Meningitis B NZ98/254 (PorA) | 59.2 (52.22 to 65.86) | 76.0 (69.66 to 81.53) | 80.4 (74.27 to 85.57) | 78.7 (72.05 to 84.23) | 5.2 (2.53 to 9.35) |
| Meningitis B M07-0241084 (NHBA) | 59.2 (52.22 to 65.86) | 74.0 (67.54 to 79.71) | 77.1 (70.66 to 82.62) | 80.9 (74.48 to 86.22) | 23.2 (17.57 to 29.64) |
| Meningitis A | 94.8 (90.65 to 97.47) | 100.0 (97.75 to 100.00) | 99.0 (96.05 to 99.89) | 91.1 (85.96 to 94.76) | 68.8 (61.86 to 75.15) |
| Meningitis C | 100.0 (97.68 to 100.00) | 100.0 (97.72 to 100.00) | 100.0 (97.65 to 100.00) | 96.7 (92.73 to 98.77) | 86.6 (81.06 to 90.92) |
| Meningitis W | 98.0 (94.66 to 99.46) | 96.0 (92.17 to 98.24) | 99.0 (96.01 to 99.89) | 93.3 (88.59 to 96.46) | 66.0 (59.09 to 72.36) |
| Menngitis Y | 99.0 (96.05 to 99.89) | 98.0 (94.77 to 99.47) | 96.9 (93.24 to 98.86) | 24.7 (18.79 to 31.54) | 85.4 (79.71 to 89.94) |
Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise was defined as: a) for individuals whose pre-vaccination titers were less than (\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).
| Percentage of subjects | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| Meningitis B M14459 (fHbp) | 66.0 (59.09 to 72.36) | 69.0 (62.32 to 75.09) | 66.3 (59.36 to 72.74) | 63.3 (56.09 to 70.11) | 2.1 (0.55 to 5.39) |
| Meningitis B 96217(NadA) | 80.4 (74.27 to 85.57) | 88.0 (82.74 to 92.04) | 90.5 (85.46 to 94.20) | 80.7 (74.20 to 86.06) | 2.1 (0.56 to 5.45) |
| Meningitis B NZ98/254 (PorA) | 48.0 (41.06 to 54.92) | 60.0 (53.11 to 66.58) | 58.8 (51.75 to 65.49) | 60.7 (53.35 to 67.63) | 1.0 (0.11 to 3.95) |
| Meningitis B M07-0241084(NHBA) | 21.4 (16.10 to 27.68) | 38.8 (32.18 to 45.72) | 42.1 (35.27 to 49.20) | 56.3 (48.88 to 63.54) | 2.1 (0.57 to 5.56) |
| Meningitis A | 92.7 (88.04 to 95.90) | 99.0 (96.17 to 99.89) | 98.9 (95.97 to 99.89) | 87.8 (82.14 to 92.06) | 67.4 (60.34 to 73.85) |
| Meningitis C | 90.8 (85.89 to 94.38) | 91.9 (87.21 to 95.24) | 86.6 (81.06 to 90.92) | 57.3 (49.95 to 64.40) | 52.1 (45.05 to 59.05) |
| Meningitis W | 83.3 (77.41 to 88.15) | 78.6 (72.32 to 83.90) | 74.2 (67.48 to 80.10) | 74.1 (67.04 to 80.30) | 41.1 (34.26 to 48.14) |
| Meningitis Y | 95.9 (91.93 to 98.19) | 91.9 (87.21 to 95.24) | 93.7 (89.18 to 96.65) | 11.4 (7.19 to 16.97) | 76.8 (70.36 to 82.43) |
hSBA mean ratios at 1 month after the last vaccination versus baseline were calculated in terms of GMRs i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after last vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.
| Ratio | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| Meningitis B M14459 (fHbp) | 11.17 (9.59 to 13.02) | 10.90 (9.42 to 12.62) | 10.85 (9.30 to 12.66) | 10.69 (9.12 to 12.52) | 1.16 (0.99 to 1.35) |
| Meningitis B 96217(NadA) | 21.33 (18.22 to 24.99) | 27.02 (23.22 to 31.44) | 25.66 (21.88 to 30.10) | 29.87 (25.32 to 35.24) | 1.09 (0.93 to 1.28) |
| Meningitis B NZ98/254(PorA) | 7.28 (6.11 to 8.67) | 9.20 (7.78 to 10.88) | 11.85 (9.94 to 14.13) | 11.77 (9.81 to 14.12) | 1.21 (1.01 to 1.44) |
| Meningitis B M07-0241084(NHBA) | 3.60 (3.05 to 4.25) | 4.96 (4.23 to 5.81) | 6.22 (5.27 to 7.35) | 6.98 (5.87 to 8.30) | 1.12 (0.95 to 1.33) |
| Meningitis A | 33.21 (27.55 to 40.04) | 59.36 (49.68 to 70.93) | 64.58 (53.52 to 77.93) | 30.05 (24.77 to 36.44) | 16.47 (13.62 to 19.93) |
| Meningitis C | 34.34 (27.88 to 42.30) | 28.74 (23.52 to 35.13) | 28.86 (23.40 to 35.60) | 6.35 (5.11 to 7.90) | 6.88 (5.58 to 8.49) |
| Meningitis W | 24.58 (20.72 to 29.15) | 23.21 (19.69 to 27.36) | 24.02 (20.20 to 28.56) | 18.29 (15.28 to 21.90) | 7.57 (6.37 to 8.99) |
| Meningitis Y | 106.87 (84.27 to 135.53) | 90.59 (72.18 to 113.70) | 99.76 (78.58 to 126.66) | 1.78 (1.39 to 2.28) | 44.99 (35.42 to 57.14) |
hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.
| Titers | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group |
|---|---|---|---|---|
| hSBA Adjusted GMTs Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After First Vaccination | 6.51 (5.63 to 7.52) | 8.33 (7.24 to 9.58) | 8.16 (7.08 to 9.41) | 9.45 (8.14 to 10.95) |
hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.
| Titers | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group |
|---|---|---|---|---|
| Meningitis B M14459(fHbp) | 5.50 (4.55 to 6.66) | 6.36 (5.29 to 7.65) | 4.94 (4.09 to 5.96) | 6.08 (5.00 to 7.39) |
| Meningitis B 96217 (NadA) | 8.21 (6.87 to 9.81) | 11.30 (9.51 to 13.42) | 12.18 (10.23 to 14.52) | 14.07 (11.72 to 16.89) |
| Meningitis B NZ98/254 (PorA) | 3.79 (3.10 to 4.63) | 4.83 (3.98 to 5.86) | 4.76 (3.91 to 5.79) | 5.48 (4.47 to 6.71) |
| Meningitis B M07-0241084 (NHBA) | 6.27 (5.23 to 7.52) | 7.31 (6.12 to 8.73) | 6.75 (5.65 to 8.06) | 7.69 (6.38 to 9.26) |
| Meningitis A | 31.38 (24.79 to 39.73) | 67.95 (54.07 to 85.40) | 88.29 (69.95 to 111.44) | 8.22 (6.48 to 10.44) |
| Meningitis C | 41.35 (32.39 to 52.79) | 33.76 (26.61 to 42.85) | 40.33 (31.71 to 51.29) | 11.47 (8.92 to 14.74) |
| Meningitis W | 108.91 (88.67 to 133.78) | 81.38 (66.62 to 99.42) | 92.84 (75.75 to 113.80) | 42.99 (34.66 to 53.33) |
| Meningitis Y | 75.07 (56.86 to 99.13) | 76.48 (58.31 to 100.32) | 100.30 (76.13 to 132.15) | 3.98 (3.00 to 5.30) |
Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).
| Percentage of subjects | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group |
|---|---|---|---|---|
| Meningitis B M14459 (fHbp) | 36.8 (30.24 to 43.88) | 49.5 (42.77 to 56.27) | 37.8 (31.21 to 44.69) | 42.2 (35.19 to 49.53) |
| Meningitis B 96217 (NadA) | 57.3 (50.24 to 64.11) | 66.0 (59.35 to 72.20) | 69.4 (62.65 to 75.51) | 75.8 (69.12 to 81.64) |
| Meningitis B NZ98/254 (PorA) | 29.2 (23.08 to 35.93) | 37.9 (31.48 to 44.61) | 33.7 (27.35 to 40.51) | 37.8 (30.94 to 45.04) |
| Meningitis B M07-0241084 (NHBA) | 35.1 (28.56 to 42.14) | 49.5 (42.69 to 56.33) | 37.5 (30.90 to 44.51) | 44.4 (37.33 to 51.75) |
| Meningitis A | 65.3 (58.28 to 71.75) | 73.5 (67.12 to 79.22) | 80.2 (74.01 to 85.41) | 25.6 (19.58 to 32.38) |
| Meningitis C | 89.6 (84.41 to 93.42) | 94.1 (89.90 to 96.88) | 92.8 (88.16 to 95.94) | 70.0 (62.96 to 76.35) |
| Meningitis W | 71.9 (65.16 to 77.88) | 70.6 (64.04 to 76.51) | 74.2 (67.67 to 80.00) | 52.3 (44.90 to 59.56) |
| Meningitis Y | 83.2 (77.18 to 88.02) | 81.8 (75.86 to 86.76) | 88.4 (83.05 to 92.49) | 20.0 (14.60 to 26.45) |
Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise is defined as: a) for individuals whose pre-vaccination titers were less than (\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).
| Percentage of subjects | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group |
|---|---|---|---|---|
| Meningitis B M14459 (fHbp) | 24.2 (18.52 to 30.76) | 24.3 (18.80 to 30.53) | 18.8 (13.67 to 24.86) | 25.6 (19.58 to 32.38) |
| Meningitis B 96217 (NadA) | 22.1 (16.62 to 28.51) | 34.0 (27.80 to 40.65) | 30.5 (24.31 to 37.38) | 32.6 (26.01 to 39.77) |
| Meningitis B NZ98/254 (PorA) | 20.8 (15.51 to 27.11) | 26.2 (20.57 to 32.58) | 26.8 (20.94 to 33.42) | 27.8 (21.60 to 34.72) |
| Meningitis B M07-0241084 (NHBA) | 9.6 (5.86 to 14.69) | 20.6 (15.35 to 26.84) | 13.8 (9.37 to 19.52) | 20.5 (14.94 to 27.03) |
| Meningitis A | 61.7 (54.60 to 68.42) | 71.3 (64.73 to 77.18) | 80.6 (74.37 to 85.88) | 23.3 (17.57 to 30.03) |
| Meningitis C | 54.2 (47.11 to 61.09) | 46.5 (39.78 to 53.39) | 51.0 (44.02 to 58.03) | 24.7 (18.79 to 31.54) |
| Meningitis W | 60.6 (53.53 to 67.40) | 52.0 (45.12 to 58.82) | 51.6 (44.46 to 58.71) | 39.8 (32.53 to 47.37) |
| Meningitis Y | 77.9 (71.49 to 83.38) | 75.5 (69.06 to 81.14) | 78.3 (71.76 to 83.79) | 9.0 (5.30 to 14.19) |
hSBA mean ratios at 1 month after the first vaccination versus baseline were calculated in terms of GMRs. i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after first vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted mean were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.
| Ratio | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group |
|---|---|---|---|---|
| Meningitis B M14459 (fHbp) | 2.59 (2.14 to 3.14) | 3.00 (2.49 to 3.61) | 2.33 (1.93 to 2.81) | 2.87 (2.36 to 3.48) |
| Meningitis B 96217(NadA) | 2.15 (1.80 to 2.57) | 2.96 (2.49 to 3.51) | 3.19 (2.68 to 3.80) | 3.68 (3.07 to 4.42) |
| Meningitis B NZ98/254 (PorA) | 2.16 (1.77 to 2.64) | 2.76 (2.27 to 3.34) | 2.72 (2.23 to 3.31) | 3.13 (2.55 to 3.83) |
| Meningitis B M07-0241084 (NHBA) | 1.73 (1.44 to 2.07) | 2.01 (1.69 to 2.41) | 1.86 (1.56 to 2.22) | 2.12 (1.76 to 2.55) |
| Meningitis A | 10.15 (8.02 to 12.85) | 21.97 (17.48 to 27.62) | 28.55 (22.62 to 36.04) | 2.66 (2.09 to 3.38) |
| Meningitis C | 8.08 (6.33 to 10.31) | 6.59 (5.20 to 8.37) | 7.88 (6.19 to 10.02) | 2.24 (1.74 to 2.88) |
| Meningitis W | 11.08 (9.02 to 13.60) | 8.28 (6.77 to 10.11) | 9.44 (7.70 to 11.57) | 4.37 (3.52 to 5.42) |
| Meningitis Y | 36.58 (27.70 to 48.30) | 37.26 (28.41 to 48.88) | 48.87 (37.09 to 64.39) | 1.94 (1.46 to 2.58) |
Assessed local AEs were erythema, swelling, induration and pain. Any erythema, swelling and induration is defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
| Participants | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| Erythema at Dose 1 | 17 | 19 | 18 | 9 | 7 |
| Swelling at Dose 1 | 20 | 21 | 16 | 13 | 10 |
| Induration at Dose 1 | 9 | 15 | 12 | 6 | 4 |
| Pain at Dose 1 | 89 | 100 | 95 | 88 | 52 |
| Erythema at Dose 2 | 15 | 18 | 15 | 10 | — |
| Swelling at Dose 2 | 13 | 14 | 15 | 12 | — |
| Induration at Dose 2 | 6 | 11 | 12 | 12 | — |
| Pain at Dose 2 | 87 | 97 | 95 | 87 | — |
Assessed systemic AEs were arthralgia, fatigue, nausea, headache, myalgia and fever. Any fever is defined as body temperature equal or greater than 38 degrees Celsius.
| Participants | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| Arthralgia at Dose 1 | 20 | 15 | 9 | 9 | 18 |
| Fatigue at Dose 1 | 56 | 61 | 55 | 46 | 50 |
| Nausea at Dose 1 | 16 | 23 | 14 | 13 | 14 |
| Headache at Dose 1 | 40 | 46 | 38 | 36 | 36 |
| Myalgia at Dose 1 | 34 | 29 | 27 | 21 | 28 |
| Fever at Dose 1 | 6 | 5 | 5 | 1 | 3 |
| Arthralgia at Dose 2 | 22 | 19 | 12 | 17 | — |
| Fatigue at Dose 2 | 58 | 61 | 62 | 56 | — |
| Nausea at Dose 2 | 16 | 13 | 15 | 17 | — |
| Headache at Dose 2 | 52 | 36 | 37 | 39 | — |
| Myalgia at Dose 2 | 41 | 38 | 35 | 38 | — |
| Fever at Dose 2 | 6 | 3 | 3 | 1 | — |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. An unsolicited AE is an AE that was not solicited using a Subject Diary and that was spontaneously communicated by a subjects/parent(s)/ Legally Acceptable Representative who has signed the informed consent or a solicited local or systemic adverse event that continues beyond the solicited period at day 7 after vaccination.
| Participants | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| Any unsolicited AEs- Dose 1 | 16 | 19 | 16 | 16 | 15 |
| Any unsolicited AEs- Dose 2 | 11 | 14 | 13 | 10 | — |
SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Medically attended AEs are defined as symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. AESIs are predefined (serious or non-serious) adverse events of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.
| Participants | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| SAE(s) | 0 | 2 | 1 | 2 | 0 |
| MAE(s) | 14 | 17 | 14 | 13 | 6 |
| AE(s) leading to withdrawal | 0 | 0 | 0 | 0 | 0 |
| AESI(s) | 0 | 0 | 0 | 0 | 0 |
Collected over Solicited Adverse Events were reported during the 7 days post-vaccination period and Unsolicited Adverse Events during the 30 Days post-vaccination period. Serious Adverse Events: were reported during the whole study period (from Day 1 up to Day 91).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MenABCWY Group | 0/100 (0%) | 0/100 (0%) | 94/100 (94%) |
| rMenBOMV+ACWY_S Group | 0/104 (0%) | 2/104 (1.9%) | 103/104 (99%) |
| rMenBOMV+ACWY_D Group | 0/100 (0%) | 1/100 (1%) | 98/100 (98%) |
| rMenBOMV Group | 0/94 (0%) | 2/94 (2.1%) | 94/94 (100%) |
| MenACWY Group | 0/102 (0%) | 0/102 (0%) | 80/102 (78.4%) |
| Event | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| ConcussionInjury, poisoning and procedural complications | 0/100 | 2/104 | 0/100 | 0/94 | 0/102 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/100 | 0/104 | 0/100 | 1/94 | 0/102 |
| SyncopeNervous system disorders | 0/100 | 0/104 | 0/100 | 1/94 | 0/102 |
| Tibia fractureInjury, poisoning and procedural complications | 0/100 | 0/104 | 1/100 | 0/94 | 0/102 |
| Event | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 94/100 | 102/104 | 97/100 | 93/94 | 53/102 |
| FatigueGeneral disorders | 70/100 | 74/104 | 72/100 | 63/94 | 50/102 |
| ErythemaGeneral disorders | 50/100 | 71/104 | 57/100 | 58/94 | 28/102 |
| SwellingGeneral disorders | 51/100 | 63/104 | 46/100 | 46/94 | 23/102 |
| HeadacheNervous system disorders | 60/100 | 57/104 | 54/100 | 52/94 | 36/102 |
| IndurationGeneral disorders | 44/100 | 54/104 | 49/100 | 38/94 | 19/102 |
| MyalgiaMusculoskeletal and connective tissue disorders | 50/100 | 49/104 | 45/100 | 41/94 | 28/102 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 29/100 | 29/104 | 18/100 | 19/94 | 18/102 |
| NauseaGastrointestinal disorders | 24/100 | 26/104 | 26/100 | 26/94 | 14/102 |
| PyrexiaGeneral disorders | 12/100 | 7/104 | 8/100 | 2/94 | 3/102 |
| Age, Continuous(Years) | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group | Total |
|---|---|---|---|---|---|---|
| Mean | 17.1 ± 4.34 | 16.9 ± 4.28 | 17.1 ± 4.49 | 17.4 ± 4.64 | 17.1 ± 4.57 | 17.1 ± 4.45 |
| Sex: Female, Male(Participants) | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group | Total |
|---|---|---|---|---|---|---|
| Female | 47 | 48 | 49 | 53 | 49 | 246 |
| Male | 53 | 56 | 51 | 41 | 53 | 254 |
| Race/Ethnicity, Customized(Participants) | MenABCWY Group | rMenBOMV+ACWY_S Group | rMenBOMV+ACWY_D Group | rMenBOMV Group | MenACWY Group | Total |
|---|---|---|---|---|---|---|
| Race — WHITE | 100 | 104 | 100 | 94 | 102 | 500 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jul 2018 to primary completion in Dec 2018, 5 months.
Results were first posted in Jan 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.